<DOC>
	<DOCNO>NCT00542386</DOCNO>
	<brief_summary>This phase III multi-centre study two period : first period phosphate binder lipid lower drug washout 8 week , second period double-blind , randomise , parallel group , fix dose , 12 week .</brief_summary>
	<brief_title>A Study MCI-196 Chronic Kidney Disease Subjects Dialysis With Hyperphosphatemia Dyslipidaemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Male female , 18 year age Clinically stable haemodialysis peritoneal dialysis Stable phosphate control On stabilised phosphorus diet Female childbearing potential negative serum pregnancy test Male subject must agree use appropriate contraception Current clinically significant medical comorbidities , may substantially compromise subject safety , expose undue risk , interfere significantly study procedure , opinion Investigator , make subject unsuitable inclusion study . A serum albumin level &lt; 30.0g/L A PTH level &gt; 1000pg/mL A body mass index ( BMI ) &lt; = 16.0kg/㎡ = &gt; 40.0kg/㎡ A serum LDLC level &gt; 4.94mmol/L ( 190mg/dL ) A serum triglycerides level &gt; 6.76mmol/L ( 600mg/dL ) A History significant gastrointestinal motility problem A positive test HIV 1 2 antibody A history substance alcohol abuse within last year Seizure disorder A history drug allergy A temporary catheter vascular access Participated clinical study experimental medication last 30 day experimental biological product within last 90 day prior sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Phosphate binder</keyword>
</DOC>